The GHDX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the GHDX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The GHDX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View GHDX Detailed Price Forecast - CNN Money||View GHDX Detailed Summary - Google Finance|
|View GHDX Detailed Summary - Yahoo! Finance||View GHDX Stock Research & Analysis - Zacks.com|
|View GHDX Trends & Analysis - Trade-Ideas||View GHDX Major Holders - Barrons|
|View GHDX Call Transcripts - NASDAQ||View GHDX Breaking News & Analysis - Seeking Alpha|
|View GHDX Annual Report - CompanySpotlight.com||View GHDX OTC Short Report - OTCShortReport.com|
|View GHDX Fundamentals - TradeKing||View GHDX SEC Filings - Bar Chart|
|View Historical Prices for GHDX - The WSJ||View Performance/Total Return for GHDX - Morningstar|
|View the Analyst Estimates for GHDX - MarketWatch||View the Earnings History for GHDX - CNBC|
|View the GHDX Earnings - StockMarketWatch||View GHDX Buy or Sell Recommendations - MacroAxis|
|View the GHDX Bullish Patterns - American Bulls||View GHDX Short Pain Metrics - ShortPainBot.com|
|View GHDX Stock Mentions - StockTwits||View GHDX Stock Mentions - PennyStockTweets|
|View GHDX Stock Mentions - Twitter||View GHDX Investment Forum News - Investor Hub|
|View GHDX Stock Mentions - Yahoo! Message Board||View GHDX Stock Mentions - Seeking Alpha|
|View Insider Transactions for GHDX - SECform4.com||View Insider Transactions for GHDX - Insider Cow|
|View GHDX Major Holdings Summary - CNBC||View Insider Disclosure for GHDX - OTC Markets|
|View Insider Transactions for GHDX - Yahoo! Finance||View Institutional Holdings for GHDX - NASDAQ|
|View GHDX Stock Insight & Charts - FinViz.com||View GHDX Investment Charts - StockCharts.com|
|View GHDX Stock Overview & Charts - BarChart||View GHDX User Generated Charts - Trading View|
Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?
Posted on Monday April 09, 2018
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intrinsic Calculation For Genomic Health Inc (NASDAQ:GHDX) Shows Investors Are Overpaying
Posted on Friday March 30, 2018
How far off is Genomic Health Inc (NASDAQ:GHDX) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock isRead More...
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Posted on Friday March 30, 2018
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized SAN DIEGO and REDWOOD CITY, Calif. ...
Landmark TAILORx Results Aid in Assessing the Effect of Chemotherapy in Women with Early-stage Breast Cancer and Oncotype DX Breast Recurrence Score® Results of 11 to 25
Posted on Thursday March 15, 2018
REDWOOD CITY, Calif., March 15, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) was informed by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, has achieved sufficient information to render a conclusion regarding the effect of chemotherapy in early-stage breast cancer patients with Recurrence Score® results of 11 to 25. This primary study group represents approximately 100,000 women diagnosed each year in the United States alone. ECOG-ACRIN will be submitting the results as a late-breaking abstract for presentation at an upcoming major medical meeting. The TAILORx trial was independently designed and conducted by ECOG-ACRIN under the sponsorship of the National Cancer Institute (NCI), part of the National Institutes of Health.